| 000 | 01391 a2200373 4500 | ||
|---|---|---|---|
| 005 | 20250517200124.0 | ||
| 264 | 0 | _c20180605 | |
| 008 | 201806s 0 0 eng d | ||
| 022 | _a2214-109X | ||
| 024 | 7 |
_a10.1016/S2214-109X(17)30467-9 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLi, Bernadette | |
| 245 | 0 | 0 |
_aTranexamic acid for treatment of women with post-partum haemorrhage in Nigeria and Pakistan: a cost-effectiveness analysis of data from the WOMAN trial. _h[electronic resource] |
| 260 |
_bThe Lancet. Global health _c02 2018 |
||
| 300 |
_ae222-e228 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntifibrinolytic Agents _xeconomics |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aNigeria _xepidemiology |
| 650 | 0 | 4 |
_aPakistan _xepidemiology |
| 650 | 0 | 4 |
_aPostpartum Hemorrhage _xdrug therapy |
| 650 | 0 | 4 | _aPregnancy |
| 650 | 0 | 4 | _aQuality-Adjusted Life Years |
| 650 | 0 | 4 | _aRisk |
| 650 | 0 | 4 |
_aTranexamic Acid _xeconomics |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aMiners, Alec | |
| 700 | 1 | _aShakur, Haleema | |
| 700 | 1 | _aRoberts, Ian | |
| 773 | 0 |
_tThe Lancet. Global health _gvol. 6 _gno. 2 _gp. e222-e228 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S2214-109X(17)30467-9 _zAvailable from publisher's website |
| 999 |
_c28033215 _d28033215 |
||